APO Research
Talk to an analyst

APO RESEARCH · REPORT

SGLT2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global SGLT2 Inhibitors Market Outlook and Growth Opportunities 2026

30 December 2025192 pages

Choose your research edition.

Industry ResearchSGLT2 Inhibitors Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal SGLT2 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal SGLT2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SGLT2 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal SGLT2 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global SGLT2 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the SGLT2 Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the SGLT2 Inhibitors market include Chia Tai-Tianqing Pharmaceutical, Sandoz, Johnson and Johnson, Merck, Kelun Pharmaceutical, Hengrui Medicine, Hansoh Pharmaceutical Group, Boehringer Ingelheim and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global SGLT2 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SGLT2 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SGLT2 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the SGLT2 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

SGLT2 Inhibitors Segment by Company

Chia Tai-Tianqing Pharmaceutical

Sandoz

Johnson and Johnson

Merck

Kelun Pharmaceutical

Hengrui Medicine

Hansoh Pharmaceutical Group

Boehringer Ingelheim

Bristol-Myers Squibb

AstraZeneca

Starpharma

Orifarm

SGLT2 Inhibitors Segment by Type

Dapagliflozin

Canagliflozin

Canagliflozin

Other

SGLT2 Inhibitors Segment by Application

Single Drug

Combination Medication

SGLT2 Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global SGLT2 Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions SGLT2 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify SGLT2 Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze SGLT2 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SGLT2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the SGLT2 Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SGLT2 Inhibitors industry.

Chapter 3: Detailed analysis of SGLT2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of SGLT2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of SGLT2 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. SGLT2 Inhibitors Industry Trends Table 2. SGLT2 Inhibitors Industry Drivers Table 3. SGLT2 Inhibitors Industry Opportunities and Challenges Table 4. SGLT2 Inhibitors Industry Restraints Table 5. Global SGLT2 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global SGLT2 Inhibitors Revenue Share by Company (2021-2026) Table 7. Global SGLT2 Inhibitors Sales Volume by Company (Pcs) & (2021-2026) Table 8. Global SGLT2 Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global SGLT2 Inhibitors Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global SGLT2 Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global SGLT2 Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global SGLT2 Inhibitors Company, Product Type & Application Table 13. Global SGLT2 Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global SGLT2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dapagliflozin Table 18. Significant Companies of Canagliflozin Table 19. Significant Companies of Canagliflozin Table 20. Significant Companies of Other Table 21. Global SGLT2 Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (Pcs) Table 22. Global SGLT2 Inhibitors Sales Volume by Type (2021-2026) & (Pcs) Table 23. Global SGLT2 Inhibitors Sales Volume by Type (2027-2032) & (Pcs) Table 24. Global SGLT2 Inhibitors Sales Volume Share by Type (2021-2026) Table 25. Global SGLT2 Inhibitors Sales Volume Share by Type (2027-2032) Table 26. Global SGLT2 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global SGLT2 Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global SGLT2 Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global SGLT2 Inhibitors Sales Value Share by Type (2021-2026) Table 30. Global SGLT2 Inhibitors Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Single Drug Table 32. Significant Companies of Combination Medication Table 33. Global SGLT2 Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (Pcs) Table 34. Global SGLT2 Inhibitors Sales Volume by Application (2021-2026) & (Pcs) Table 35. Global SGLT2 Inhibitors Sales Volume by Application (2027-2032) & (Pcs) Table 36. Global SGLT2 Inhibitors Sales Volume Share by Application (2021-2026) Table 37. Global SGLT2 Inhibitors Sales Volume Share by Application (2027-2032) Table 38. Global SGLT2 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global SGLT2 Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global SGLT2 Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global SGLT2 Inhibitors Sales Value Share by Application (2021-2026) Table 42. Global SGLT2 Inhibitors Sales Value Share by Application (2027-2032) Table 43. Global SGLT2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (Pcs) Table 44. Global SGLT2 Inhibitors Sales by Region (2021-2026) & (Pcs) Table 45. Global SGLT2 Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global SGLT2 Inhibitors Sales by Region (2027-2032) & (Pcs) Table 47. Global SGLT2 Inhibitors Sales Market Share by Region (2027-2032) Table 48. Global SGLT2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global SGLT2 Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global SGLT2 Inhibitors Sales Value Share by Region (2021-2026) Table 51. Global SGLT2 Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global SGLT2 Inhibitors Sales Value Share by Region (2027-2032) Table 53. Global SGLT2 Inhibitors Market Average Price (US$/Pcs) by Region (2021-2026) Table 54. Global SGLT2 Inhibitors Market Average Price (US$/Pcs) by Region (2027-2032) Table 55. Global SGLT2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (Pcs) Table 56. Global SGLT2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global SGLT2 Inhibitors Sales by Country (2021-2026) & (Pcs) Table 58. Global SGLT2 Inhibitors Sales Market Share by Country (2021-2026) Table 59. Global SGLT2 Inhibitors Sales by Country (2027-2032) & (Pcs) Table 60. Global SGLT2 Inhibitors Sales Market Share by Country (2027-2032) Table 61. Global SGLT2 Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global SGLT2 Inhibitors Sales Value Market Share by Country (2021-2026) Table 63. Global SGLT2 Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global SGLT2 Inhibitors Sales Value Market Share by Country (2027-2032) Table 65. Chia Tai-Tianqing Pharmaceutical Company Information Table 66. Chia Tai-Tianqing Pharmaceutical Business Overview Table 67. Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 68. Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Product Portfolio Table 69. Chia Tai-Tianqing Pharmaceutical Recent Development Table 70. Sandoz Company Information Table 71. Sandoz Business Overview Table 72. Sandoz SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 73. Sandoz SGLT2 Inhibitors Product Portfolio Table 74. Sandoz Recent Development Table 75. Johnson and Johnson Company Information Table 76. Johnson and Johnson Business Overview Table 77. Johnson and Johnson SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 78. Johnson and Johnson SGLT2 Inhibitors Product Portfolio Table 79. Johnson and Johnson Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 83. Merck SGLT2 Inhibitors Product Portfolio Table 84. Merck Recent Development Table 85. Kelun Pharmaceutical Company Information Table 86. Kelun Pharmaceutical Business Overview Table 87. Kelun Pharmaceutical SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 88. Kelun Pharmaceutical SGLT2 Inhibitors Product Portfolio Table 89. Kelun Pharmaceutical Recent Development Table 90. Hengrui Medicine Company Information Table 91. Hengrui Medicine Business Overview Table 92. Hengrui Medicine SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 93. Hengrui Medicine SGLT2 Inhibitors Product Portfolio Table 94. Hengrui Medicine Recent Development Table 95. Hansoh Pharmaceutical Group Company Information Table 96. Hansoh Pharmaceutical Group Business Overview Table 97. Hansoh Pharmaceutical Group SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 98. Hansoh Pharmaceutical Group SGLT2 Inhibitors Product Portfolio Table 99. Hansoh Pharmaceutical Group Recent Development Table 100. Boehringer Ingelheim Company Information Table 101. Boehringer Ingelheim Business Overview Table 102. Boehringer Ingelheim SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 103. Boehringer Ingelheim SGLT2 Inhibitors Product Portfolio Table 104. Boehringer Ingelheim Recent Development Table 105. Bristol-Myers Squibb Company Information Table 106. Bristol-Myers Squibb Business Overview Table 107. Bristol-Myers Squibb SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 108. Bristol-Myers Squibb SGLT2 Inhibitors Product Portfolio Table 109. Bristol-Myers Squibb Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 113. AstraZeneca SGLT2 Inhibitors Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Starpharma Company Information Table 116. Starpharma Business Overview Table 117. Starpharma SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 118. Starpharma SGLT2 Inhibitors Product Portfolio Table 119. Starpharma Recent Development Table 120. Orifarm Company Information Table 121. Orifarm Business Overview Table 122. Orifarm SGLT2 Inhibitors Sales (Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 123. Orifarm SGLT2 Inhibitors Product Portfolio Table 124. Orifarm Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. SGLT2 Inhibitors Distributors List Table 128. SGLT2 Inhibitors Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. SGLT2 Inhibitors Product Image Figure 2. Global SGLT2 Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global SGLT2 Inhibitors Sales (2021-2032) & (Pcs) Figure 5. Global SGLT2 Inhibitors Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global SGLT2 Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dapagliflozin Image Figure 10. Canagliflozin Image Figure 11. Canagliflozin Image Figure 12. Other Image Figure 13. Global SGLT2 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (Pcs) Figure 14. Global SGLT2 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global SGLT2 Inhibitors Sales Volume Share by Type (2021-2032) Figure 16. Global SGLT2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global SGLT2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global SGLT2 Inhibitors Sales Value Share by Type (2021-2032) Figure 19. Single Drug Image Figure 20. Combination Medication Image Figure 21. Global SGLT2 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (Pcs) Figure 22. Global SGLT2 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global SGLT2 Inhibitors Sales Volume Share by Application (2021-2032) Figure 24. Global SGLT2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global SGLT2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global SGLT2 Inhibitors Sales Value Share by Application (2021-2032) Figure 27. Global SGLT2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (Pcs) Figure 28. Global SGLT2 Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global SGLT2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global SGLT2 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 32. North America SGLT2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. Europe SGLT2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific SGLT2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. South America SGLT2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa SGLT2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa SGLT2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt SGLT2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. SGLT2 Inhibitors Value Chain Figure 126. Manufacturing Cost Structure Figure 127. SGLT2 Inhibitors Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Dapagliflozin
  • Canagliflozin
  • Canagliflozin
  • Other
Applications
  • Single Drug
  • Combination Medication
Companies covered
  • Chia Tai-Tianqing Pharmaceutical
  • Sandoz
  • Johnson and Johnson
  • Merck
  • Kelun Pharmaceutical
  • Hengrui Medicine
  • Hansoh Pharmaceutical Group
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • AstraZeneca
  • Starpharma
  • Orifarm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global SGLT2 Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global SGLT2 Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global SGLT2 Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 SGLT2 Inhibitors Market Dynamics
  1. 2.1 SGLT2 Inhibitors Industry Trends
  2. 2.2 SGLT2 Inhibitors Industry Drivers
  3. 2.3 SGLT2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 SGLT2 Inhibitors Industry Restraints
3 SGLT2 Inhibitors Market by Company
  1. 3.1 Global SGLT2 Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global SGLT2 Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global SGLT2 Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global SGLT2 Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global SGLT2 Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global SGLT2 Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global SGLT2 Inhibitors Company Product Type and Application
  8. 3.8 Global SGLT2 Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global SGLT2 Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 SGLT2 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 SGLT2 Inhibitors Market by Type
  1. 4.1 SGLT2 Inhibitors Type Introduction
  2. 4.1.1 Dapagliflozin
  3. 4.1.2 Canagliflozin
  4. 4.1.3 Canagliflozin
  5. 4.1.4 Other
  6. 4.2 Global SGLT2 Inhibitors Sales Volume by Type
  7. 4.2.1 Global SGLT2 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global SGLT2 Inhibitors Sales Volume by Type (2021-2032)
  9. 4.2.3 Global SGLT2 Inhibitors Sales Volume Share by Type (2021-2032)
  10. 4.3 Global SGLT2 Inhibitors Sales Value by Type
  11. 4.3.1 Global SGLT2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global SGLT2 Inhibitors Sales Value by Type (2021-2032)
  13. 4.3.3 Global SGLT2 Inhibitors Sales Value Share by Type (2021-2032)
5 SGLT2 Inhibitors Market by Application
  1. 5.1 SGLT2 Inhibitors Application Introduction
  2. 5.1.1 Single Drug
  3. 5.1.2 Combination Medication
  4. 5.2 Global SGLT2 Inhibitors Sales Volume by Application
  5. 5.2.1 Global SGLT2 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global SGLT2 Inhibitors Sales Volume by Application (2021-2032)
  7. 5.2.3 Global SGLT2 Inhibitors Sales Volume Share by Application (2021-2032)
  8. 5.3 Global SGLT2 Inhibitors Sales Value by Application
  9. 5.3.1 Global SGLT2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global SGLT2 Inhibitors Sales Value by Application (2021-2032)
  11. 5.3.3 Global SGLT2 Inhibitors Sales Value Share by Application (2021-2032)
6 SGLT2 Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global SGLT2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SGLT2 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global SGLT2 Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global SGLT2 Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global SGLT2 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global SGLT2 Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global SGLT2 Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global SGLT2 Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global SGLT2 Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America SGLT2 Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America SGLT2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe SGLT2 Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe SGLT2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific SGLT2 Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific SGLT2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America SGLT2 Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America SGLT2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa SGLT2 Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa SGLT2 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 SGLT2 Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global SGLT2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global SGLT2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global SGLT2 Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global SGLT2 Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global SGLT2 Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global SGLT2 Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global SGLT2 Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global SGLT2 Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt SGLT2 Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt SGLT2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt SGLT2 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai-Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Product Portfolio
  6. 8.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz SGLT2 Inhibitors Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Johnson and Johnson
  14. 8.3.1 Johnson and Johnson Company Information
  15. 8.3.2 Johnson and Johnson Business Overview
  16. 8.3.3 Johnson and Johnson SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson SGLT2 Inhibitors Product Portfolio
  18. 8.3.5 Johnson and Johnson Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck SGLT2 Inhibitors Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Kelun Pharmaceutical
  26. 8.5.1 Kelun Pharmaceutical Company Information
  27. 8.5.2 Kelun Pharmaceutical Business Overview
  28. 8.5.3 Kelun Pharmaceutical SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kelun Pharmaceutical SGLT2 Inhibitors Product Portfolio
  30. 8.5.5 Kelun Pharmaceutical Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine SGLT2 Inhibitors Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
  37. 8.7 Hansoh Pharmaceutical Group
  38. 8.7.1 Hansoh Pharmaceutical Group Company Information
  39. 8.7.2 Hansoh Pharmaceutical Group Business Overview
  40. 8.7.3 Hansoh Pharmaceutical Group SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hansoh Pharmaceutical Group SGLT2 Inhibitors Product Portfolio
  42. 8.7.5 Hansoh Pharmaceutical Group Recent Developments
  43. 8.8 Boehringer Ingelheim
  44. 8.8.1 Boehringer Ingelheim Company Information
  45. 8.8.2 Boehringer Ingelheim Business Overview
  46. 8.8.3 Boehringer Ingelheim SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim SGLT2 Inhibitors Product Portfolio
  48. 8.8.5 Boehringer Ingelheim Recent Developments
  49. 8.9 Bristol-Myers Squibb
  50. 8.9.1 Bristol-Myers Squibb Company Information
  51. 8.9.2 Bristol-Myers Squibb Business Overview
  52. 8.9.3 Bristol-Myers Squibb SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb SGLT2 Inhibitors Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca SGLT2 Inhibitors Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Starpharma
  62. 8.11.1 Starpharma Company Information
  63. 8.11.2 Starpharma Business Overview
  64. 8.11.3 Starpharma SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Starpharma SGLT2 Inhibitors Product Portfolio
  66. 8.11.5 Starpharma Recent Developments
  67. 8.12 Orifarm
  68. 8.12.1 Orifarm Company Information
  69. 8.12.2 Orifarm Business Overview
  70. 8.12.3 Orifarm SGLT2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Orifarm SGLT2 Inhibitors Product Portfolio
  72. 8.12.5 Orifarm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 SGLT2 Inhibitors Value Chain Analysis
  2. 9.1.1 SGLT2 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 SGLT2 Inhibitors Sales Mode & Process
  6. 9.2 SGLT2 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 SGLT2 Inhibitors Distributors
  9. 9.2.3 SGLT2 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst